Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831505 · ClinicalTrials.gov registry record · Phase 1
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
A Phase 1 study, sponsored by Presage Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01831505: Completed Phase 1 study, sponsored by Presage Biosciences.
NCT01831505 is a Phase 1 study that has completed, run by Presage Biosciences. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01831505, a Phase 1 study, has completed, sponsored by Presage Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Many cancer patients are prescribed drugs to which their cancer is already resistant - and thus suffer toxicity with no potential for benefit. Previous attempts to assess chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human patients with newly diagnosed or recurrent lymphoma to determine how human cancerous lymph nodes in situ respond to standard of care therapeutics precisely microinjected with the CIVO(tm) microdosing system.
Interventions
- DRUG Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
What the finished NCT01831505 record still lists
NCT01831505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them is the first listed.
NCT01831505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01831505 about?
NCT01831505 is a clinical study titled "Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents". Many cancer patients are prescribed drugs to which their cancer is already resistant - and thus suffer toxicity with no potential for benefit. Previous attempts to assess chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human patients with newly diagnosed or recurr...
What is the current status of trial NCT01831505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2012-11. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01831505?
The interventions under investigation include: Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them (DRUG).
Who is sponsoring clinical trial NCT01831505?
This trial is sponsored by Presage Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01831505's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia